-
CBG Producer Willow Biosciences Reports Record Q2 Revenue, Enters Major Pharma Deal Slated To Be Key Driver Of Growth
Monday, August 12, 2024 - 3:30pm | 539Read More...Willow Biosciences Inc. (TSX: WLLW) (OTCQB:CANSF) reported its financial and operating results on Monday for the three months ended June 30, 2024, reporting significantly higher revenue and reduced costs. “The second quarter was marked by significant pipeline and revenue growth with the...
-
Company Exploring CBG Production Signals New Era Of Commercial Success In Synthetic Biology
Wednesday, January 10, 2024 - 3:38pm | 668Read More...Biotech company Willow Biosciences Inc. (TSX:WLLW) (OTCQB:CANSF) generated nearly $1.3 million in revenues in 2023, increasing approximately 60% over the period. Dr. Chris Savile, president and CEO of the company called 2023 a "transformative year for Willow," which relies on synthetic biology...
-
Willow Biosciences Q1 FY23 Revenue Grows To $203K, Still In Development Stage And On 'A Solid Trajectory'
Friday, May 12, 2023 - 10:17am | 581Read More...Willow Biosciences Inc. (OTCQB: CANSF) (TSX:WLLW) released its financial and operating results for the three months ended March 31, 2023, revealing revenue of CA$274,000 ($203,000) compared to no revenue in Q1 2022. The company is in the development stage and expects to operate at a loss and...
